Skip to main content
Premium Trial:

Request an Annual Quote

Genmab Plans to Delist from Neuer Markt

SAN FRANCISCO, Aug. 7 - Copenhagen, Denmark-based Genmab will no longer trade on Germany's Neuer Markt of the Frankfurt Stock Exchange as of the close of the market on August 16, the company said today.

 

Genmab, developer of fully-human antibodies, will continue to be listed on the Copenhagen Stock Exchange.

 

More than 95 percent of the company's stock is traded on the Copenhagen Stock Exchange, and delisting from the Neuer Markt will eliminate costs associated with double listing, Genmab CEO Lisa Drakeman said in a statement.

 

Click here for more information.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.